| Project/Area Number |
08457301
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Shimane Medical University |
|---|
Principal Investigator |
TAMURA Katsuhiro Shimane Medical University, 1st Dept.of Surgery, Professor, 医学部, 教授 (80155259)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NIO Yoshinori Shimane Medical University, 1st Dept.of Surgery, Associate Professor, 医学部, 助教授 (20208119)
長見 晴彦 島根医科大学, 医学部, 助手 (50180518)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥7,300,000 (Direct Cost: ¥7,300,000)
Fiscal Year 1997: ¥3,700,000 (Direct Cost: ¥3,700,000)
Fiscal Year 1996: ¥3,600,000 (Direct Cost: ¥3,600,000)
|
|---|
| Keywords | pancreatic cancer / clinical stage / oncogene / tumor suppressor gene / growth factor / prognostic factor |
|---|
| Research Abstract |
The present project was designed to develope a new clinical stage classification of pancreatic cancer. The previous classification included just clinicopathological factors, but pancreatic cancer can not always be classified by this standard stage, because pancreatic cancer shows extremely malignant potentials. In the present study, we assessed the cytomolecular backgrounds of pancreatic cancer using various gene techniques and immunohistochemistry with monoclonal antibodies. The cytomolecular factors included Ki-ras point mutation and the expression of p53 tumor suppressor gene product, EGF and its receptor, fibronectin and Ki-ras p21.
The results show that the expression of p53 tumor suppressor gene product, coexpression of EGF and EGF-receptor, and Ki-ras double mutation were suggested to be the indicators for poor prognosis of the patients with pancreatic cancer, independently of clinicopathological factors such as depth of tumor invasion, nodal involvement or distant metastasis.
We conclude that these cytomolecular parameters are beneficial to predict the prognosis of the pancreatic cancer patients and the clinical stage should include the status of these parameters.
|
